

| Medical Policies   |  |                    |                |
|--|--|--------------------|----------------|
| Policy Title   | Summary  | Products Affected  | Effective Date |
| Adstiladrin  | Ad hoc review. <ul style="list-style-type: none"> <li>Updated Medicare Variation.</li> </ul>   | Medicare Advantage | 1/1/2026       |
| Continuous Glucose Monitors  | Annual review. <ul style="list-style-type: none"> <li>Changed order of paragraphs in eligibility criteria, but no changes made to criteria themselves.</li> </ul>  | All products       | 1/1/2026       |
| Homeless Medical Respite Services                                    | New policy; formerly part of the Long-Term Services and Supports policy.   | One Care and SCO   | 1/1/2026       |
| Insulin Pumps  | Annual review. <ul style="list-style-type: none"> <li>No changes.</li> </ul>   | All Products       | 1/1/2026       |
| Long-Term Services and Supports                                      | Ad hoc review of policy. <ul style="list-style-type: none"> <li>Separated Homeless Medical Respite Services criteria into its own policy.</li> <li>Added criteria from former Respite Services policy into this policy.</li> </ul>         | One Care and SCO   | 1/1/2026       |
| Omisirge   | Ad hoc review. <ul style="list-style-type: none"> <li>Updated Medicare variation.</li> </ul>   | Medicare Advantage | 1/1/2026       |
| Personal Care Attendant and Personal Care Management Agency Services | Ad hoc review of policy. <ul style="list-style-type: none"> <li>Added criteria for Personal Care Management Agency services.</li> <li>Added criteria for Complex Care services.</li> </ul>   | One Care and SCO   | 1/1/2026       |
| Respite Services   | Retired separate policy; added the criteria to the Long-Term Services and Supports policy.   | One Care and SCO   | 1/1/2026       |
| Vitamin D Testing and Screening in Adults                            | Annual review. <ul style="list-style-type: none"> <li>No changes.</li> </ul>   | All products       | 1/1/2026       |
| Prime Therapeutics: Abecma   | Ad hoc review. <ul style="list-style-type: none"> <li>Clarified difference between auth durations for initial and renewal periods.</li> <li>REM criterion removed.</li> <li>Added NCCN guidance for additional uses of regimen.</li> </ul> | Commercial         | 2/1/2026       |
| Prime Therapeutics: Aucatzyl   | Ad hoc review.   | Commercial         | 2/1/2026       |

|                              |  |            |          |
|------------------------------|--|------------|----------|
|                              | <ul style="list-style-type: none"> <li>• Clarified difference between auth durations for initial and renewal periods.</li> <li>• Updated FDA indications and NCCN guidance.</li> <li>• Updated code list.</li> </ul>                             |            |          |
| Prime Therapeutics: Breyanzi | Ad hoc review. <ul style="list-style-type: none"> <li>• Clarified difference between auth durations for initial and renewal periods.</li> <li>• REM criterion removed.</li> <li>• Expanded access per NCCN guidance.</li> </ul>                  | Commercial | 2/1/2026 |
| Prime Therapeutics: Carvykti | Ad hoc review. <ul style="list-style-type: none"> <li>• Clarified difference between auth durations for initial and renewal periods.</li> <li>• REM criterion removed.</li> <li>• Added NCCN guidance for additional uses of regimen.</li> </ul> | Commercial | 2/1/2026 |
| Prime Therapeutics: Kymriah  | Ad hoc review. <ul style="list-style-type: none"> <li>• Clarified difference between auth durations for initial and renewal periods.</li> <li>• REM criterion removed.</li> <li>• Expanded access per NCCN guidance.</li> </ul>                  | Commercial | 2/1/2026 |
| Prime Therapeutics: Ryoncil  | New policy.  | Commercial | 2/1/2026 |
| Prime Therapeutics: Tecartus | Ad hoc review. <ul style="list-style-type: none"> <li>• Clarified difference between auth durations for initial and renewal periods.</li> <li>• REM criterion removed.</li> <li>• Updated info on patient monitoring.</li> </ul>                 | Commercial | 2/1/2026 |
| Prime Therapeutics: Yescarta | Ad hoc review. <ul style="list-style-type: none"> <li>• Clarified difference between auth durations for initial and renewal periods.</li> <li>• REM criterion removed.</li> <li>• Updated criteria based on NCCN guidelines.</li> </ul>          | Commercial | 2/1/2024 |